Clinical reference Biomarker Directory
Back to directory

Human Transforming Growth Factor beta 1

Emerging

TGF-β1 drives tissue fibrosis and tumor immune evasion; blocking it is an active cancer immunotherapy combination research area.

Also known as TGF-beta 1 TGFB1
In plain language

TGF-beta 1 has complicated effects: it drives scarring/fibrosis in some tissues and helps some tumors hide from the immune system. Combining TGF-beta-blocking drugs with existing cancer immunotherapies is an active area of clinical research.

Biomarker & context

Transforming growth factor beta 1 (TGF-β1) is a cytokine with complex, context-dependent roles in fibrosis, wound healing, and immune regulation.

What it indicates

Elevated TGF-β1 is implicated in tissue fibrosis (including radiation-induced fibrosis) and in tumor immune evasion, where cancers exploit TGF-β signaling to suppress the anti-tumor immune response.

Diagnosis & clinical testing

TGF-β1 is not yet a standardized diagnostic blood test in routine clinical practice; it's primarily assessed in research settings, tissue studies, and clinical trial biomarker analyses for fibrosis and cancer immunotherapy research.

Guiding treatment

TGF-β is an active target of investigational cancer immunotherapy combinations, since blocking TGF-β signaling alongside checkpoint inhibitors (like PD-1/PD-L1 blockers) is being studied as a way to overcome tumor immune evasion and improve immunotherapy response rates.

Clinical significance

Not yet a standardized clinical diagnostic test; primarily relevant in fibrosis and cancer immunotherapy research settings.

References
  1. General oncology/immunology reference literature on TGF-β1 in fibrosis and cancer immune evasion research.